RUNX1 accounts for about 10% of MDS cases (the third most frequently mutated gene in MDS) and is typically a subclonal mutation associated with unfavorable clinical outcomes and advanced disease. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.